Burlington Stores Inc vs Johnson & Johnson — how do they compare? Burlington Stores Inc trades at $354.86 (market cap $22.59B), while Johnson & Johnson trades at $260.51 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 27.7× Burlington Stores Inc's market cap, and Johnson & Johnson pays a 2.06% dividend while Burlington Stores Inc pays none. Which is the better fit depends on your goals.
| BURL | JNJ | |
|---|---|---|
Market Cap | $22.59B | $626.09B |
Sector | Consumer Cyclical | Health |
52-Week High | $372.19 | $267.24 |
52-Week Low | $242.43 | $172.78 |
Enterprise Value | $27.71B | $654.37B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.06% |
Signals from Pluang's Aura AI — not financial advice
Burlington Stores (BURL) trades at $353.63, down 4.81% in the last session but maintains strong fundamental momentum with consistent earnings beats and robust revenue growth. The stock shows a bullish technical setup with key support at $346 and resistance at $365, while fundamentals reveal impressive profitability with 39.14% ROE and expanding margins. Recent news highlights the company's successful smaller-store strategy and upward revised 2026 outlook.
BURL presents a compelling growth opportunity with 94% analyst buy ratings and a $367 consensus target offering 3.8% upside. However, elevated valuation multiples (P/E 36.92) and competitive retail pressures warrant caution. The company's debt-to-asset ratio rising to 20.99% in 2026 and recent insider selling of $619,200 worth of shares represent notable risk factors for investors.
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Trailing returns across standard periods
Latest headlines on both assets
Burlington is a leading off-price retailer in the US, offering branded apparel, footwear, and home goods at significant discounts. It operates hundreds of stores focused on delivering high-quality products at great value.
Read more on BURL →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →